ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bcl-2 Inhibitor LOXO-338

Also written as “LOXO-338”, “FCN-338 + Azacitidine” and “FCN-338 + erythromycin+ Ara-C”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Myeloid, Acute, led by 2 companies.

Drug pageBcl-2 Inhibitor LOXO-338: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 4, 20253 company-led studies, 2 open or runningNext primary completion: Dec 1, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma22 open or runningphase 2since Feb 4, 2025Dec 10, 2020Dec 1, 2026phase 2 · NCT06858618
Eli Lillyits history only10 open or runningphase 1since Aug 25, 2021Aug 25, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Fosun Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 10, 2020First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT04682808 · 99 enrolled · China
  2. Feb 4, 2025Phase 2 study in Leukemia, Myeloid, AcuteNCT06858618 · 47 enrolled · China

Ahead

  1. Dec 1, 2026Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT06858618

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Fosun Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06858618Leukemia, Myeloid, Acute · China2Active, not recruitingDec 1, 202647
NCT04682808Leukemia, Lymphocytic, Chronic, B-Cell · China1Active, not recruitingApr 28, 202499

How it is read

Names in the registry

  • “LOXO-338”, 1 entry
  • “FCN-338 + Azacitidine”, 1 entry
  • “FCN-338 + erythromycin+ Ara-C”, 1 entry
  • “FCN-338”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.